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method of identifying previously unknown susceptibility 
genes, which highlight microglial receptors as promising 
novel targets for therapeutic modulation. Multi-photon in 
vivo microscopy has provided a method of directly visu-
alizing the effects of manipulation of these target genes. 
Here, we review the latest findings and concepts emerging 
from the rapidly growing body of literature exemplified 
for Rett syndrome and late-onset, sporadic Alzheimer’s 
disease.
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Introduction
For decades, microglia have been conspicuously absent 
from most neuroscientific discussions regarding the criti-
cal players in the workings of the brain. If microglia were 
mentioned at all, it was more often than not in terms of 
their pathological role in neuroinflammation. Only very 
recently have these cells come under more careful consid-
eration as to their unique place in the network of the central 
nervous system (CNS). As such, microglia have recently 
been revealed to be surprisingly more nimble and nuanced 
than previously imagined in their ability to respond to 
their surrounding environment. In the review that follows, 
we will discuss key studies highlighting the extraordinary 
roles these cells have now been shown to play in both CNS 
development and decline. In the development, we focus on 
the role of microglia in Rett syndrome; in decline, we look 
at microglia as major players in Alzheimer’s disease (AD) 
pathology.
Abstract Microglia, the tissue-resident macrophages 
of the brain, are attracting increasing attention as key 
players in brain homeostasis from development through 
aging. Recent works have highlighted new and unex-
pected roles for these once-enigmatic cells in both healthy 
central nervous system function and in diverse patholo-
gies long thought to be primarily the result of neuronal 
malfunction. In this review, we have chosen to focus on 
Rett syndrome, which features early neurodevelopmental 
pathology, and Alzheimer’s disease, a disorder associated 
predominantly with aging. Interestingly, receptor-medi-
ated microglial phagocytosis has emerged as a key func-
tion in both developmental and late-life brain pathologies. 
In a mouse model of Rett syndrome, bone marrow trans-
plant and CNS engraftment of microglia-like cells were 
associated with surprising improvements in pathology—
these benefits were abrogated by block of phagocytic 
function. In Alzheimer’s disease, large-scale genome-
wide association studies have been brought to bear as a 
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Microglia: the tissue‑resident macrophages of the brain
Microglia are ubiquitous throughout the CNS, and are esti-
mated to represent approximately 10 % of all cells found 
within the brain [70]. Microglia are unique within the brain 
in many ways, but perhaps primarily so in that they are true 
immune cells, originating during primitive hematopoiesis 
in the yolk sac as CX3CR1-expressing tissue-resident mac-
rophage precursors [39]. Subsequently, precursors become 
migratory, move into the nascent brain, and proliferate in 
situ [1]. Recent lineage tracing experiments have sug-
gested that expression of runt-related transcription factor 
(Runx)1, Pu.1 and Irf8 are critical, and that establishment 
of the brain vasculature is necessary for the infiltration of 
the CNS by these cells [39, 62, 63].
Cellular origin will frequently dictate function, and 
microglia share provenance with other tissue-resident mac-
rophages [38, 45]. Thus, it can be expected that microglia 
should perform well as phagocytes, producers of cytokines, 
and of growth factors, as necessary [2]. Indeed, this has 
been shown to be the case. However, the nature of the tissue 
surrounding a cell will also impact upon its phenotype, and 
certainly microglia must ply their trade in immediate prox-
imity to delicate neurons. Therefore, it is not surprising that 
molecules found in the CNS milieu act to modulate micro-
glial function accordingly. TGF-β1, for instance, plays a 
major role in dampening microglial cytokine production, 
with loss having been shown to be associated with neuronal 
death and pathological microglial activation/microgliosis as 
measured at postnatal day 21 [15]. It is important to point 
out that the mouse model used succumbs to autoimmune-
mediated lethality early in adulthood. In another recent 
work, TGF-β1−/− mice in which T cell production of TGF-
β is preserved, thus preventing the abovementioned periph-
eral autoimmune wasting phenotype, were shown to suf-
fer from severe microglia deficiency, indicating that CNS 
tissue-resident macrophages and their surrounding tissue 
may engage in dynamic and mutual support [18]. The fact 
remains, however, that certain aspects of these two works 
are in conflict, and clearly more research is needed to better 
define the precise role for TGF-β in microglial function and 
survival. Fractalkine is another such modulatory molecule 
produced by neural cells, suggested to act directly on the 
microglial CX3CR1 receptor to prevent neurotoxicity [19, 
71]. Thus, microglia are bona fide immune cells, but like 
other tissue-resident macrophages, they are also uniquely 
positioned to provide benefit and homeostatic support to 
the tissue within which they reside, in this case, the CNS. 
Microglia must be dynamic, but also judicious and meas-
ured in their responses. Moreover, microglial phenotype 
has been suggested to be plastic [104]. Yet, as guardians of 
the brain, they need to also possess the ability to respond 
vigorously to pathological insults when appropriate. Along 
these lines, recently developed imaging techniques have 
revealed that microglia are surprisingly dynamic cells, 
rather than inactive unless provoked, as was long believed 
[89].
Microglia are active participants in developing brain
Microglia were long thought to be “quiescent” cells except 
during pathological insult; this notion, however, has lately 
been powerfully challenged by two-photon imaging studies 
indicating that microglia are in a state of perpetual surveil-
lance even in healthy brain [89]. Resting microglia display 
highly ramified processes. Under physiological conditions, 
these processes are highly motile, constantly sampling their 
environment, while the soma remains stationary [28, 89]. 
In addition to performing active surveillance, microglia are 
also the professional phagocytes of the brain, and, as such, 
must be involved in unremitting cleanup of cellular corpses 
and debris. Phagocytosis of apoptotic cells is a necessary 
part of normal tissue development [101], and is thus inte-
gral to the role of microglia as tissue-resident macrophage. 
During the process of brain maturation, millions of neurons 
undergo apoptosis, yet leave barely a trace—thanks to vigi-
lant corpse removal attributable largely to microglia [126]. 
Similarly, in experiments involving induced massive abla-
tion of cells within the brain parenchyma, there is little—
if any—detectable debris to be found even days after [95]. 
It is all the more striking that phagocytosis of apoptotic 
neurons is not merely a passive response. The active role 
of microglia in prompting apoptosis during development is 
well-illustrated by studies which demonstrate that deficien-
cies in microglial CD11b and DAP12, important in mye-
loid activation phenotype, were associated with impairment 
in hippocampal development [123].
Based on findings in these works and others, it is likely 
that impairment of normal microglial function—particu-
larly during early life—could be expected to have serious 
implications regarding normal brain development. A dys-
regulated or deficient immune response could contribute 
significantly to pathologies seen in neurodevelopmental 
disorders involving abnormal dendritic arborization and 
dendritic spine maintenance. Along these lines, it was dem-
onstrated in a series of studies that an interplay between 
several cell types in the CNS was ultimately responsible 
for the pruning of synapses by microglia in the visual sys-
tem. Immune complement factors, namely C1q and C3, 
were shown to be expressed on neurons [113] as a result of 
TGF-β signaling by astrocytes [10] and recognized by cog-
nate receptors expressed exclusively in brain parenchyma 
by microglia [103]. Pruning was suggested to be activity 
dependent [119] in works that correlated light depriva-
tion and re-exposure with dynamic interactions between 
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microglia and synapses [103] and directly by showing 
increased microglial phagocytosis of synaptic inputs cor-
responding to tetrodotoxin-mediated silencing compared to 
those activated by forskolin [103]. while these studies were 
conducted largely with a focus on the developing visual 
system, these results imply that similar microglial dysfunc-
tion in other brain areas could impact powerfully on synap-
tic maintenance and neural network activity, as is suggested 
to be important in autistic spectrum pathologies. A recently 
published work indeed suggests that network function 
and social behavior are impaired as a result of microglial 
deficiency and compromised microglial–neuron signaling 
[130].
In vivo imaging of microglia in mouse models of AD
The same methodology that has revealed the surprisingly 
dynamic role of microglia—two-photon microscopy [29]—
has enabled in vivo long-term imaging studies and allowed 
monitoring of morphological and functional changes in the 
living mouse brain under normal and pathological condi-
tions [72, 111]. A recent in vivo imaging study revealed 
that microglia cells undergo age-related morphological 
changes such as increased soma volume and a shortening 
of the processes [46]. Interestingly, aged mice exhibited 
increased microglial soma movement in comparison to 
younger mice, but this effect was diminished in response to 
acute injury by laser lesion [46]. Under pathological condi-
tions, such as AD and in mouse models of AD, microglial 
cells are tightly associated with and cluster around dense 
core amyloid plaques [54], which are the major neuro-
pathological hallmark of AD and are thought to be toxic to 
the surrounding neural tissue [17, 67, 82, 83, 112]. In terms 
of morphology, microglia display a reactive phenotype in 
AD with typically short, thickened and less ramified pro-
cesses [54, 81, 116]. In the aged human brain, ‘dystrophic’ 
de-ramified microglia have been described with fragmented 
processes and bulbous swellings [115]. However, a simi-
lar dystrophic phenotype resembling morphological signs 
of aging has not yet been seen in the rodent brain. Instead, 
microglia in the rodent brain appear to be less complex [26, 
46, 120]. In a mouse model of AD with plaque pathology, 
microglia had shorter processes (Fig. 1b) and less process 
movement compared to younger pre-depositing transgenic 
mice indicating, that age may impact the aforementioned 
morphological changes [65]. Nonetheless, the functional 
consequences of these morphological changes remain 
poorly understood and need further study.
Acute two-photon imaging identified that microglia 
cells surrounding Aβ plaques were morphologically mainly 
hypertrophic and amoeboid, whereas in plaque-free areas 
of the brain, ramified microglia were predominantly evident 






















Fig. 1  Aberrant microglia in models of Rett syndrome and Alzhei-
mer’s disease. a Representative captures of phagocytosing microglia 
(labeled with anti-CD11b, green) incubated for 2 h with TAMRA-
labeled Uv-irradiated neural progenitor cells (red). b Representative 
confocal images of microglia in a pre-depositing 6-week-old 5xFAD 
transgenic mouse and activated microglia encompassing plaques in a 
24-week-old 5xFAD transgenic mouse. Note the shortened and less 
ramified processes. Green labeling is GFP expressed under the con-
trol of the CX3CR1 promoter; red fluorescence depicts Aβ plaques 
labeled with an anti-Aβ antibody. Scale bars: a 25 µm and b left 
panel 50 µm; right panel 20 µm
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towards newly formed plaques [83], suggesting that they 
might transform into a hypertrophic or even amoeboid cell 
type in response to Aβ plaque formation and could have a 
pathological role. Recently, several in vivo imaging studies 
have monitored the appearance and growth of Aβ plaques 
[16, 47, 80, 83], which is of importance for the pathologi-
cal development of AD. Plaque growth might be restricted 
by microglia removing and phagocytosing Aβ fibrils [11, 
110]. This idea is supported by two immunization studies 
that provided in vivo evidence that microglia are able to 
phagocytose Aβ [4, 65]. The precise role of microglia in the 
pathogenesis of AD remains, however, poorly understood 
and the microglia response to plaques remains controver-
sial. Surprisingly, microglial depletion in a mouse model 
of AD changed neither the plaque count nor the size of 
plaques [40]. However, microglia were only depleted for 
4 weeks, and in older mice, which might explain the lack 
of effect.
In addition to plaques, AD is also characterized by mas-
sive neurodegeneration and neuronal cell loss, and several 
studies have tried to unravel how microglial activation 
might influence this neuronal loss. A combination of two-
photon microscopy and laser ablation demonstrated that 
microglia cells adjacent to the site of injury polarized their 
processes towards the lesion to contain the injury [28]. In 
the context of AD, the neuronal cell loss in another triple 
transgenic mouse model of AD [91] was rescued after cross-
breeding with mice lacking the CX3CR1 receptor, indicat-
ing a crucial role of the microglial chemokine receptor in 
mediating neuronal apoptosis in AD [36]. Other studies 
using CX3CR1-deficient mice showed exacerbated levels of 
phospho-Tau and elevated Tau pathology in Tau transgenic 
mice [9, 22], while CX3CR1 deficiency reduced amyloid 
load in AD mouse models with numerous Aβ deposits [71, 
74]. Interestingly, neuronal and behavioral deficits worsened 
in CX3CR1-deficient mice and were plaque independent 
[22]. Despite these compelling results, the precise role of 
microglia in the pathogenesis of AD remains enigmatic. we 
predict two-photon microscopy will help shed light on the 
contribution of microglia to this devastating disease.
In the following sections, we take a look at evidence 
from genetic analyses that suggest a basis for immune 
abnormalities in Rett syndrome, previously considered to 
be a disease solely of neurons, and also summarize genetic 
approaches that have led to the recent discovery of a num-
ber of new AD risk and susceptibility factors including 
inflammation.
Mecp2 as a regulator of immune‑related genes
Rett syndrome is an X-linked CNS developmental disorder 
grouped with the autism spectrum disorders. Rett syndrome 
is linked in the majority of cases to mutations in the methyl-
CpG-binding protein 2 (MeCP2) gene [3], which acts to 
modulate transcription at the level of chromatin remod-
eling by partnering with cofactors such as Sin3A in the 
formation of repressor complexes [21]. Interestingly, it was 
shown that Mecp2 functions as both activator and repressor 
of transcription, thereby complicating the predicted results 
of mutation of the gene. Regardless, mutation of MeCP2 
has been definitively linked to major disruptions of CNS 
and somatic function which together underly Rett syn-
drome pathology. Rett syndrome symptoms include psy-
chomotor impairment, locomotor deficits, tremors, apneas, 
osteopenia, scoliosis, intestinal dysfunction and severe 
mental retardation [109]. MeCP2 is an epigenetic regulator 
of thousands of downstream genes and is expressed in most 
cells, including at high levels in immune tissues [107]. 
while several investigations into genes dysregulated as a 
result of Mecp2 deletion have been performed to date, the 
genes selected for further analysis have been those previ-
ously implicated in neuronal, rather than glial or immune 
function. However, microarray analyses of neural tissue 
from Mecp2-deficient mice have consistently included 
immune genes, e.g., Irak-1 [58], as among the most highly 
aberrant in transcription as a result of loss of Mecp2. Along 
these lines, MeCP2 was recently named as a candidate 
susceptibility gene for systemic lupus erythematosus, an 
autoimmune disorder [124]. Nevertheless, research into 
immune system abnormalities in Rett syndrome has been 
surprisingly limited. In the few such studies conducted to 
date, however, it has become increasingly clear that muta-
tions in MeCP2 can greatly modify the expression of genes 
influencing the function of immune cells. Thus, it is not 
surprising that Mecp2 has been directly connected to reg-
ulation of genes including FoxP3, a defining marker of T 
regulatory cells [68], and interferon (IFN)-γ, produced by 
several immune cell types including T lymphocytes and 
myeloid cells [118]. Notably, dysregulated IFN-γ produc-
tion by T cells was recently suggested to be key to periph-
eral immune pathology common in Mecp2 duplication syn-
drome, a disease similar in severity to Rett syndrome, but 
caused by overexpression of Mecp2 rather than deficiency 
[129]. More recently, it was shown that Mecp2 plays a role 
in the generation of TH1 and TH17 cells by the regulation of 
microRNA-124. This latest work is notable in that it eluci-
dates a mode of gene regulation by Mecp2 that is separate 
from its canonical function in chromatin modification [56].
Clinical data from Rett syndrome patients regarding 
immune function present a picture of overall dysregula-
tion, but studies are few; thus, overarching patterns are 
still unclear. In general, the picture painted may be one of 
immune insufficiency rather than one implicating Mecp2-
mutant immune cells as “bad actors”. For example, CD25-
positive T lymphocytes were undetected in blood analyzed 
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from Rett syndrome patients [98] indicating the possibil-
ity of activated effector T and T regulatory cell deficiency, 
both of which express CD25. Interestingly, an unrelated 
study showed increased serum levels of soluble CD25 [33] 
in serum from Rett syndrome patients. Increased soluble 
CD25 has been linked to both T regulatory and T effector 
cell repression. Additionally, a decrease in CD8+ T lym-
phocytes and natural killer cells has also been shown.
In sum, while several groups have focused on elucida-
tion of downstream genetic targets of Mecp2 in neurons or 
whole brain tissue, these data, while intriguing, have not as 
yet revealed many potential critical regulatory molecules 
that might serve as targets for manipulation. However, one 
that has shown some promise, first in mouse models [121] 
and now in Stage two clinical trials, is insulin-like growth 
factor (IGF)-1 [61]. It is perhaps noteworthy that microglia 
are a major producer of IGF-1 in the brain, thus supporting 
the notion of a central role for these immune cells in Rett 
syndrome pathobiology.
GWAS studies for identifying risk genes in AD
Familial AD (FAD) is caused by specific, identifiable, 
autosomal dominant mutations in the Amyloid Precur-
sor Protein (APP), Presenilin 1 and/or Presenilin 2 and is 
characterized by an early onset of the disease. However, the 
majority of AD patients suffer from sporadic AD, which 
has no definitive genetic cause. The etiology of sporadic 
AD is largely unknown, but environmental factors and 
genetic predisposition may be risk factors for the disease.
Recently, genome-wide association studies (GwAS) 
have emerged as an effective tool for identifying several 
new risk genes for Alzheimer’s disease. The most com-
mon risk factor for sporadic AD is the Apoe4 allele, which 
increases the risk of developing the disease by three times 
for heterozygous carriers and by 15 times for homozygous 
carriers [64]. Other genes, such as CLU, Bin1 or PICALM 
have also been identified as risk genes for AD [44, 52, 69, 
105]. Among the genes identified as risk factors for AD 
were genes expressed by microglia. For example CD33 was 
identified as a sporadic AD risk locus [8, 50, 87]. CD33 is 
a transmembrane protein and a member of the sialic acid-
binding immunoglobulin-like lectins (Siglecs). Its activ-
ity has been linked to triggering endocytosis and patho-
gen recognition, however, its function in the brain is still 
unknown [25]. Several new studies have recently exam-
ined the role of CD33 in AD. CD33 expression was found 
to be increased in circulating monocytes in carriers of the 
rs3865444C risk allele and was associated with dimin-
ished internalization of Aβ peptide [13]. CD33 expression 
is also increased in the brains of AD patients and protein 
levels are specifically increased in the frontal cortex by 
twofold. Furthermore, CD33 expression in microglia is cor-
related with AD pathology, whereas the deletion of CD33 
in a mouse model of AD lowered cortical and hippocam-
pal Aβ plaque burden. Finally, in vitro experiments in Bv2 
cells with increased levels of CD33 diminished microglial 
uptake of Aβ, while the degradation was unaffected [41]. 
The authors implicated CD33 as a regulator of microglial 
clearance of Aβ and proposed it as a target for the treatment 
and prevention of AD.
Two recent reports linked another innate immune recep-
tor and known microglial Aβ clearing molecule, trig-
gering receptor expressed on myeloid 2 cells (TReM2) 
to increased risk of sporadic AD [42, 57]. TReM2 acts 
through DAP12 and, loss-of-function mutations lead to 
presenile dementia with bone cysts, also known as Nasu–
Hakola disease [20, 94]. The function of this receptor in 
general and specifically its role in the pathogenesis of AD 
is not well understood. In the human and mouse cerebral 
cortex, TReM2 is predominantly expressed in microglia 
and to a much lesser amount in neurons [106]. TReM2 
seems to be crucial for brain homeostasis, since its activa-
tion stimulates the phagocytic activity in microglia with-
out causing inflammation [117]. In APP transgenic mice, 
TReM2 is up-regulated in microglial cells in the vicinity 
of amyloid plaques [34]. However, Nasu–Hakola disease 
patients do not overly develop Aβ plaques and therefore the 
relevance of TReM2 in sporadic AD needs to be investi-
gated further.
Interestingly, CD33 and TReM2 both were found to 
be linked to DAP12 [131]. As aforementioned, DAP12 is 
crucial for normal brain development and for the clearance 
of apoptotic neurons. The authors used an integrated sys-
tems approach and ranked network structures for their rel-
evance in sporadic AD. DAP12 was identified as being in 
the center of this microglial network and unifying previous 
top GwAS risk loci including CD33.
In the final sections, we suggest immune approaches 
aimed at the possible amelioration of Rett syndrome and 
Alzheimer’s disease, and highlight some critical functions 
of microglia, that, when impaired, may provide clues that 
link these seemingly disparate brain pathologies.
Immune‑directed treatments in Rett syndrome
while MeCP2 is highly expressed in neurons, it is also 
expressed in many other cells and tissues, including micro-
glia [78] (Kipnis Lab, personal communication). Rett 
pathology was originally believed to be solely due to altera-
tion or loss of Mecp2 expression in neurons; however, 
more recent data suggest that glia also play a major role in 
the disease [6, 78]. For example, expression of wild-type 
Mecp2 in astrocytes of otherwise Mecp2-null mice was 
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shown to significantly block disease progression [73]. It was 
also proposed that Mecp2-null microglia might be directly 
damaging neuronal dendrites via supranormal production of 
glutamate [78]. In parallel, our analysis of primary micro-
glia revealed a striking impairment of phagocytic capability 
by Mecp2-null microglia as compared to controls (Fig. 1a). 
Subsequent examination of brain tissue revealed increased 
levels of debris in Mecp2-null mice, suggesting that insuf-
ficient clearance of debris by Mecp2-null microglia could be 
a key factor contributing to Rett pathology [30].
If intrinsic impairment of microglia as a result of Mecp2 
deficiency were important to pathology, then supplementa-
tion of the CNS with wild-type microglia might be expected 
to yield benefit. A strategy of bone marrow transplant was 
previously shown by several groups to result in engraftment 
of microglia-like cells within brain parenchyma [84, 99] and 
such methods have been employed with some modest suc-
cess in human disease in the treatment of globoid cell leu-
kodystrophy (Krabbe disease) and related metabolic storage 
diseases associated with CNS pathology [51, 66]. Murine 
studies using the twitcher mouse model for Krabbe disease 
preceded clinical therapies, and showed CNS and peripheral 
engraftment followed by significant remyelination [51].
Indeed, Mecp2-null mice that received bone mar-
row transplant displayed remarkably blunted pathology. 
Although still different from wild-type mice, treated mice 
significantly outlived both Mecp2-null mice transplanted 
with Mecp2-null bone marrow and untreated controls. 
when brains from transplanted mice were examined, robust 
engraftment of microglia-like cells in brain parenchyma 
was observed, suggesting that arrest was associated with 
improved ability of wild-type microglia to support Mecp2-
null neurons. Results from bone marrow transplant were 
supported by results from a complementary genetic/phar-
macological approach using LysmcreMecp2lox-stop/y mice, in 
which arrest was achieved wild-type Mecp2 was driven in 
a significant proportion of myeloid cells, including micro-
glia, on an otherwise Mecp2-null background. These mice 
were treated with chronic injections of annexin v, shown 
to be effective in binding to phosphatidylserine residues 
exposed on apoptotic cells and critical for corpse recogni-
tion and removal. As expected, blocking recognition and 
uptake of debris in these mice by annexin administration 
resulted in abolishment of disease arrest and significant 
increase in TUNeL-positive debris in brains. These data 
strongly suggested that arrest was being mediated in other-
wise Mecp2-null mice by the ability of wild-type microglia 
to effectively clear debris in CNS.
A further possibility is a scenario in which micro-
glia may also be deficient in production of growth factors 
needed to maintain neural cells. Along these lines, it was 
recently shown that acute ablation of microglia or abla-
tion of BDNF production by microglia resulted in deficits 
in dendritic spine elimination and behavioral impairments 
in motor learning, fear conditioning, and novel object rec-
ognition [95]. Similarly, mice deficient in hematopoietic-
specific BDNF production exhibited pathological levels 
of hyperphagia and insulin resistance. IBA1-positive cells 
in brain parenchyma of these animals were visualized 
in hypothalamus in contact with neurons that are shown 
to control feeding. Importantly, BDNF-competent cells 
engrafted into hypothalamus following intracerebroven-
tricular injection were associated with reversal of patholog-
ical feeding phenotype [122].
These works and others suggest the strong possibility 
that pathologies conventionally considered to be the result 
of isolated neural dysfunction may in fact be influenced 
significantly—and even caused in some cases—by micro-
glial dysfunction. Along these lines, recent studies now 
highlight a central role for microglia, and more specifically 
microglial receptors in Alzheimer’s disease, a pathology 
classically associated with aging brain, but long assumed to 
be primarily of neuron-intrinsic etiology.
Immune‑receptors on microglia as therapeutic target 
for the treatment of AD
Microglia are the major phagocytic cells in the brain which 
become activated upon contact with Aβ [81]. To date, com-
pelling evidence is lacking as to whether microglia are 
truly able to phagocytose Aβ [100]. This occurrence would 
not only involve the engulfment of the protein, but also a 
degradation step (degradation of Aβ), which has yet to be 
proven. without the capability to degrade Aβ, it seems 
unlikely that amyloid-containing microglia can clear addi-
tional Aβ but instead may even transform into toxic cells. 
Nevertheless, growing evidence suggests that microglia are 
able to prevent or decelerate AD by promoting the clear-
ance of Aβ. Several microglial receptors seem to play a 
pivotal role in the clearance of Aβ (Fig. 2). One of these 
receptors involved in the clearance of Aβ is the scaven-
ger receptor expressed on microglia Scara-1. Scara-1 pro-
motes the binding and phagocytosis of Aβ in vitro [31], 
and in vivo in a mouse model of AD [35]. Isolated human 
microglia also bind Aβ via Scara-1 receptor [53]. Fur-
thermore, microglia that decorate Aβ plaques in a mouse 
model of AD showed increased levels of Scara-1 [12], 
whereas microglia isolated from Scara-1 knockout mice 
had reduced Aβ clearance capacity compared to wild-type 
cells [23]. Scara-1 deficiency increased Aβ plaque pathol-
ogy in APPPS1 transgenic mice and accelerated the disease 
whereas pharmacological up-regulation of Scara-1 on mon-
onuclear phagocytes had the opposite effect and increased 
clearance of Aβ [35] emphasizing the relevance of Scara-1 
in the pathogenesis of AD.
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Another microglial receptor for Aβ of the scavenger 
receptor family is CD36. CD36 binds Aβ fibrils and is 
expressed on microglia in the AD brain [24]. Addition-
ally, CD36 mediates reactive oxygen species production 
in response to Aβ [24] and microglial recruitment to the 
site of aggregated fibrillar Aβ in vivo [32]. Investigation 
of the signaling molecules of microglial CD36 upon Aβ 
stimulation helped to identify Src family members such 
as Fyn and Lyn as well as MAPK [85]. There have been 
attempts to increase the phagocytic activity of microglia 
via peroxisome proliferator-activated receptor γ (PPARγ) 




































FcγRIIb Scara-1 CD36 Rage Beclin-1 Trem2 CD33
Fig. 2  Regulation of microglial phagocytosis via receptors. a, 
b Summary of known receptors expressed on microglia and an 
autophagic protein that are involved in the phagocytosis of Aβ and are 
described in the context of AD pathology. The faint gray shadow in 
the background represents a plaque surrounded by several microglia. 
Arrows indicate increased or decreased receptor expression in AD. 
Receptor shapes are not meant to represent actual receptor structures
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mice. This enhancement of microglial Aβ phagocytosis was 
shown to be mediated by the CD36 receptor [127]. Inter-
estingly, CD36 is a co-receptor as it can form a heterodi-
meric complex with TLR-4 and TLR-6. The interaction of 
Aβ with this receptor complex on microglia provokes an 
inflammatory response with IL-1β production indicative of 
inflammasome activation [114].
This is well in line with the finding that microglial 
Beclin-1 is also impaired in AD and regulates phagocytic 
receptor function. Beclin-1 is known for its role in the 
autophagosomal system, which is in turn implicated in AD. 
early in AD progression, Beclin-1 expression and protein 
levels in the human enthorinal cortex decrease [97]. A het-
erozygous deletion of Beclin-1 in a mouse model for AD 
increased the accumulation of intraneuronal and extracel-
lular Aβ, most likely due to the accumulation of APP and 
its metabolites [55, 97]. Beclin-1 is important for efficient 
phagocytosis by microglia in vitro and in vivo. Reduced 
Beclin-1 expression also caused microglial changes; micro-
glia and microglia-like cell culture lines deficient for Bec-
lin-1 were only able to clear a minor amount of Aβ aggre-
gates [75]. The author further claims that together with 
its binding partner vps34, Beclin-1 regulates a retromer 
complex which is among others involved in receptor recy-
cling. Interestingly, reduced Beclin-1 levels also dimin-
ished phagocytic receptor recycling for TReM2 and CD36, 
which both are linked to microglial impairment in AD and 
are discussed as well in this review.
Another microglial receptor reported to bind to Aβ is 
FcγRIIb. FcγRIIb is expressed on most leucocytes exclud-
ing natural killer cells. It contains an ITIM in its cytoplas-
mic domain which recruits phosphatases in turn resulting 
in an inhibition of cell activation (for review see [92]). Like 
other FcRs, FcγRIIb is widely expressed in the central 
nervous system, and is important for cerebral function and 
development, especially for Purkinje cells [88]. However, 
its role in AD still remains elusive. The first hint came from 
a study by Peress et al. 1993, identifying FcγR immuno-
reactivity on microglia and in senile plaques distributed 
throughout the white matter and cortex in healthy and AD 
brains [96]. This was further extended and confirmed with 
the finding that FcγRIIb was specifically up-regulated in 
the hippocampus of AD brains [59]. From immunization 
studies, there is evidence for FcγRIIb-mediated phagocyto-
sis by microglia that increases the clearance of Aβ plaques 
in vivo [5, 7]. However, another immunization study using 
FcγR knockout mice did not conclude that FcγRIIb-
mediated phagocytosis was the crucial phagocytic mecha-
nism [27]. A recent paper linked Aβ oligomers and FcγIIb 
receptor binding as a possible cause of neurotoxicity by 
activating caspase-12 and boosting endoplasmic reticu-
lum stress markers [59]. Furthermore, oligomer-specific 
antibodies to Aβ lead to increased neurotoxicity of Aβ in 
a mixed culture of primary neuronal and glial cells. Both 
the depletion of the Fc region and the removal of microglia 
from the culture diminished this effect implicating micro-
glia as a crucial mediator of neuronal death [86]. Inhibi-
tion of the Aβ–FcyR interaction could be a new therapeutic 
approach for AD and might bring a revival of immunization 
trials.
Yet another example of a receptor involved in the 
pathogenesis of AD is the receptor of advanced glycation 
end products (RAGe) that has also been shown to bind 
to Aβ [128]. RAGe is expressed in multiple cell types, 
including microglia and is up-regulated in hippocampal 
microglia of AD brains (see review by [77]). The interac-
tion of RAGe with Aβ has diverse implications on inflam-
matory responses, neuronal function and the elevation of 
amyloidosis. Microglial activation elicited from the bind-
ing of Aβ to RAGe produced cytokines such as IL-1β 
and TNF-α, which in turn might lead to the clustering 
of microglia around Aβ plaques [76, 128]. Furthermore, 
microglial RAGe signaling through p38MAPK and JNK 
released IL-1β, leading to synaptic dysfunction [93]. In a 
mouse model for systemic amyloidosis, the use of an anti-
RAGe antibody significantly reduced amyloid plaque for-
mation. Although promising results have been achieved 
with the RAGe inhibitor PF-04494700 from Pfizer in pre-
clinical studies in transgenic mice and in a 10-week Phase 
2 trial [102], the follow-up Phase 2 trial over 18 months 
was halted because of serious side effects and worsened 
cognitive decline in the higher dose treatment group. In 
contrast, the lower dose group did not raise safety con-
cerns and some analyses showed decreased decline on the 
Alzheimer’s Disease Assessment Scale-cognitive (ADAS-
cog), but other clinical and biomarker measures failed to 
show significant differences between low-dose and pla-
cebo group (for information see http://clinicaltrials.gov) 
[37].
Developmental and age‑related CNS pathologies: is 
microglia dysfunction a common element?
while Rett syndrome and Alzheimer’s disease are clearly 
different in terms of time of age of onset and pathological 
sequelae, in terms of microglial dysfunction as a contribut-
ing factor, they may indeed have much in common. As was 
detailed previously, in a mouse model of Rett syndrome, 
data suggest that the ability of microglia to respond effi-
ciently to a buildup of apoptotic corpses during develop-
ment may be one of the many keys to the postnatal onset 
of pathology. Phagocytosis of apoptotic neurons has long 
been recognized as necessary to normal brain development, 
and more recently, it is suggested that microglia also play a 
critical role in the synaptic pruning process.
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Similarly, as covered earlier in this review, GwAS stud-
ies and other genetic screening techniques have identified 
microglial receptors as strongly up- or down-regulated in 
the Alzheimer’s disease brain. For instance, during the pro-
gression of AD, the expression of several Aβ binding recep-
tors such as the Scara-1, CD36 and RAGe decreased by 
two- to fivefold in microglia, and thereby lost their ability 
to clear Aβ [49]. Taken together, these studies provide the 
basic rationale for the development of further therapeutic 
strategies targeting microglia, e.g., enhancing the ability of 
microglia to clear Aβ by an up-regulation of these micro-
glial receptors (Fig. 2).
Dysregulated inflammatory response may also repre-
sent a common mechanism by which microglial impair-
ment contributes to pathology in both diseases. Mecp2 is 
a known regulator of NFκB though multiple pathways, 
including via the aforementioned Irak1, and also through 
direct regulation of the IκBα promoter [79]. Along these 
lines, it was recently shown that loss of Mecp2 in immune 
cells, including neonatal mouse microglia and siRNA-
treated human monocytes, led to supranormal production 
of glutaminase via an NFκB-dependent process [90]. Glu-
tamate is well-recognized as a factor in neurotoxicity, and 
unrestrained production within the confines of the CNS 
by microglia would conceivably lead to adverse effects on 
neuronal function. The possibility of dendritic and synaptic 
damage mediated by microglia-derived glutamate was pre-
viously proposed as an underlying factor in Rett syndrome 
pathology [78].
In the context of AD, the NLRP3 inflammasome path-
way in microglia has been elucidated over the last few 
years as possibly being of critical importance. Fibrillar 
Aβ was shown to activate the NLRP3 inflammasome with 
IL-1β secretion by microglia [43]. Interestingly, inhibition 
of phagocytosis reversed this effect and resulted in reduced 
NLRP3-mediated IL-1β release [43]. As mentioned above, 
CD36 is able to bind to Aβ [125], and its uptake was shown 
to promote NLRP3 activation and amyloid aggregation at 
least in cell culture experiments [108]. More in vivo evi-
dence for the involvement of the NLRP3 inflammasome 
pathway in the pathogenesis of AD came recently from 
a study by Heneka et al. which clearly demonstrated an 
increase in caspase-1 activation in diseased human AD 
brains. Furthermore, NLRP3 deficiency in APP transgenic 
mice decreased Aβ plaque load, suggesting a prominent 
role of NLRP3 in the pathogenesis of AD and a potential 
target for therapeutic intervention [48].
Conclusion
The long-held view that microglia are at best inactive 
unless provoked by pathogens, and at worst “the enemy 
within” [60] has recently been challenged by several high-
profile studies. Lineage tracing and genetic analysis have 
revealed that microglia share origins with other tissue-res-
ident macrophages [38, 39], thus suggesting an important 
homeostatic role in tissue maintenance, a trademark func-
tion of resident macrophages. In support of this notion, 
in vivo imaging has revealed, that microglia are indeed 
dynamic surveyors of the brain’s milieu, even during health 
[89]. During development, microglia are now shown to 
be necessary for pruning of supernumerary synapses and 
clearance of apoptotic neurons [103, 119]. Accordingly, 
deficiencies in phagocytic function may be linked to autis-
tic spectrum disorders, which frequently present with den-
dritic pruning defects. In the aging brain, microglia have 
been similarly implicated as mediators of both healthy 
function and pathology. Aged microglia have been dem-
onstrated to display an amoeboid morphology in particular 
when associated with Aβ plaques [14], a classical hallmark 
of AD pathology. Along these lines, it has become increas-
ingly clear that expression of key receptors on microglia 
may be linked to their response to Aβ, shifting them to 
either ameliorative or aggressive phenotype.
Thus, the dogmatic view of microglial response solely 
as an indicator of pathology is becoming revised as it 
becomes clear that microglial inactivity is as dangerous 
as overreaction. we should seek to encourage a robust and 
well-tuned response from microglia, rather than a dimin-
ished response, as necessary for maintained CNS health.
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